Výsledky vyhledávání - "PD‐(L)1 inhibitor"

Akademický článek

Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study

Autor: Yang H, Yang T, Qiu G, Liu J

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 1435-1443 (2023)

Hui Yang, Tiequan Yang, Guangpin Qiu, Jie Liu Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, People’s Republic of ChinaCorrespondence: Hui Yang, Department of Interventional Therapy, Ningbo NO.2 Hospital, No. 41, Xibe

Externí odkaz: https://doaj.org/article/f544b2320f1c438ab8fc314988798ae0

Zobrazit plný text záznamu

Akademický článek

An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor

Autor: Zegui Tu, Yang Yu, Tian Tian, Caili Li, Jieyan Luo

Publikováno v: Heliyon, Vol 9, Iss 10, Pp e20465- (2023)

Background: Our study aimed to build a risk stratification system predicting the progression-free survival (PFS) to classify patients into diverse prognostic subgroups for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor. M

Externí odkaz: https://doaj.org/article/323899c8ba86415c883be5c340b491be

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer

Autor: Yu Chen, Xinchao Liu, Zhaoqin Huang, Kaikai Zhao, Yao Wang, Fei Ren, Jinming Yu, Xiangjiao Meng

Publikováno v: Cancer Medicine, Vol 10, Iss 23, Pp 8518-8529 (2021)

Abstract Background The safety of thoracic radiotherapy (TRT) after programmed death 1/programmed death ligand 1 (PD‐(L)1) inhibitor treatment in patients with lung cancer was scarcely reported. This retrospective study was conducted to evaluate th

Externí odkaz: https://doaj.org/article/ac1d2e6abb474baab5f2a2c63217a8f9

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors

Autor: Cédric Mahiat, Benoît Bihin, Fabrice Duplaquet, Claudia Stanciu Pop, Michael Dupont, Thierry Vander Borght, Benoît Rondelet, Jean Vanderick, Bénédicte André, Lionel Pirard, Sebahat Ocak

Publikováno v: International Journal of Molecular Sciences, Vol. 24, no.4, p. 3618 (2023)
International Journal of Molecular Sciences
Volume 24
Issue 4
Pages: 3618

Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c53dcb03e0fe5444e4a770d2c0b456e
https://hdl.handle.net/2078.1/272962

Zobrazit plný text záznamu

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer

Autor: Xinchao Liu, Zhaoqin Huang, Fei Ren, Kaikai Zhao, Xiangjiao Meng, Jinming Yu, Yao Wang, Yu Chen

Publikováno v: Cancer Medicine, Vol 10, Iss 23, Pp 8518-8529 (2021)
Cancer Medicine

Background The safety of thoracic radiotherapy (TRT) after programmed death 1/programmed death ligand 1 (PD‐(L)1) inhibitor treatment in patients with lung cancer was scarcely reported. This retrospective study was conducted to evaluate the inciden

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b270b2537565e21880276aed0450a3b
https://doi.org/10.1002/cam4.4363

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

Publikováno v: Scientia
Rao, S, Anandappa, G, Capdevila, J, Dahan, L, Evesque, L, Kim, S, Saunders, M P, Gilbert, D C, Jensen, L H, Samalin, E, Spindler, K L, Tamberi, S, Demols, A, Guren, M G, Arnold, D, Fakih, M, Kayyal, T, Cornfeld, M, Tian, C, Catlett, M, Smith, M & Spano, J P 2022, ' A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) ', ESMO Open, vol. 7, no. 4, 100529 . https://doi.org/10.1016/j.esmoop.2022.100529

PD-L1 inhibitor; Anal cancer; Retifanlimab Inhibidor de PD-L1; Cáncer anal; Retifanlimab Inhibidor de PD-L1; Càncer anal; Retifanlimab Background Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis followin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::187fd16c9a4b6f5c22835443c168b40a
https://pubmed.ncbi.nlm.nih.gov/35816951

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání